Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and11C-Labeled Pittsburgh compound B

Philipp T. Meyer, Sabine Hellwig, Florian Amtage, Christof Rottenburger, Ursula Sahm, Peter Reuland, Wolfgang A. Weber, Michael Hüll

Research output: Contribution to journalArticlepeer-review

95 Scopus citations

Abstract

PET studies with biomarkers of regional neuronal activity (cerebral glucose metabolism or blood flow [CBF]) and amyloid-β (Aβ) depositions provide complementary information for the early diagnosis of dementia and follow-up of patients with dementia. We investigated the validity of relative regional CBF estimates (R1) gained from pharmacokinetic analyses of 11C-labeled Pittsburgh compound B (11C-PIB) PET studies as a marker of neuronal activity and neurodegeneration. Methods: Twenty-two patients with cognitive impairment (16 patients with early Alzheimer disease) underwent 18F-FDG and 11C-PIB PET studies for the assessment of regional glucose metabolism and Aβ load. Parametric images of R1 (relative CBF) and binding potential (BPND; Aβ load) were generated by 2-step simplified reference tissue model (SRTM2) analyses of dynamic 11C-PIB data. Volume-of-interest and voxel-based statistical analyses were performed to investigate the association between normalized 18F-FDG uptake and 11C-PIB R1 and the correlation of these measures with symptom severity (Mini-Mental State Examination [MMSE] scores) in patients with Alzheimer disease. Results: SRTM2 analyses provided high-quality 11C-PIB R1 images that were comparable to 18F-FDG PET images. Regional 11C-PIB R 1 values strongly correlated with normalized regional 18F-FDG uptake when correlations were calculated separately for each patient (R2 [mean ± SD], 0.73 ± 0.11) or across all regions of all patients (R2, 0.62). A regression model including 18F-FDG uptake, subject identification, and region grouping (into cortical, subcortical, and limbic regions to allow for possible differences in flow/metabolism coupling) accounted for 86% of total 11C-PIB R 1 variability. Voxel-based correlation analyses of 18F-FDG uptake and 11C-PIB R1 with MMSE scores revealed similar core findings of positive correlations in the posterior cingulate gyrus/precuneus and negative correlations (preserved activity) in the bilateral sensorimotor cortex. There was no correlation between Aβ load (BP ND) and MMSE scores. Conclusion: These results strongly suggest that 11C-PIB R1 can serve as a complementary biomarker of neuronal activity and, thus, neurodegeneration in addition to Aβ load given by 11C-PIB BPND. Further studies are needed to validate the diagnostic value of dual-biomarker 11C-PIB PET studies in comparison with combined 18F-FDG and 11C-PIB PET studies. Compared with the latter, dual-biomarker 11C-PIB PET greatly reduces costs and burden for patients.

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalJournal of Nuclear Medicine
Volume52
Issue number3
DOIs
StatePublished - 1 Mar 2011
Externally publishedYes

Keywords

  • Alzheimer disease
  • C-PIB
  • PET
  • Pharmacokinetic modeling

Fingerprint

Dive into the research topics of 'Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and11C-Labeled Pittsburgh compound B'. Together they form a unique fingerprint.

Cite this